Tue, May 13, 11:02 AM (34 days ago)
**Minerva Neurosciences, Inc. (NERV) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Minerva reported no revenue for Q1 2025, consistent with previous quarters due to the lack of approved products. - **Profit Margins:** The company reported a net loss of $3.8 million for Q1 2025, an improvement from the $8.6 million loss in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $4.1 million for Q1 2025, down from $6.1 million in Q1 2024. - **Earnings Changes:** The net loss per share was $0.50 for Q1 2025, compared to $1.13 in Q1 2024. - **Cash Position:** As of March 31, 2025, Minerva had $17.4 million in cash, cash equivalents, and restricted cash. **Operational Performance:** - **R&D Expenses:** Research and development expenses decreased to $1.4 million in Q1 2025 from $4.2 million in Q1 2024, primarily due to reduced costs associated with the FDA review of roluperidone and lower compensation expenses. - **G&A Expenses:** General and administrative expenses remained stable at $2.5 million for both periods. - **Investment Income:** Investment income decreased to $158,000 in Q1 2025 from $358,000 in Q1 2024 due to lower cash balances and interest rates. **Trends & Uncertainties:** - **Regulatory Uncertainties:** Minerva received a Complete Response Letter (CRL) from the FDA for roluperidone in February 2024, requiring additional studies and data. - **Financial Uncertainties:** The company expects to continue incurring losses and negative cash flows, necessitating additional capital raising efforts. - **Listing Uncertainties:** Minerva regained compliance with Nasdaq's Net Income Rule but faces ongoing monitoring and potential delisting risks. **Future Operations Impact:** - **Capital Requirements:** Minerva will need to raise additional capital to continue operations and advance roluperidone through the regulatory process. - **Strategic Options:** The company is evaluating potential strategic options, including partnerships and collaborations, to support its development programs. - **Market Risks:** The company faces significant market risks, including competition, regulatory challenges, and the need for substantial capital investments.